ClinicalTrials.gg
Sign In
Status unknownNCT03435393Updated Feb 19, 2018

Ripple Mapping for Epicardial Mapping of Brugada Syndrome

An observational study in Brugada Syndrome, sponsored by University College London Hospitals. Status unknown at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by University College London Hospitals · Observational

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

Whether a mapping algorithm "Ripple-mapping" is able to rapidly identify the areas of long-duration multicomponent electrograms which constitute the targets for ablation for an automated strategy remains to be assessed.

02

Conditions studied

  • Brugada Syndrome

Browse trials for

03

In context

Brugada Syndrome

53 studies on the registry are indexed under Brugada Syndrome; 19 are open to participants now.

This study's planned enrollment of 10 is below the median of 155 across 34 observational studies indexed under Brugada Syndrome.

Browse Brugada Syndrome studies →

Lead sponsor

University College London Hospitals is the lead sponsor of 62 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Brugada syndrome and an episode of ventricular tachycardia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Brugada syndrome patients requiring ablation

Exclusion criteria

Exclusion Criteria:

  • Patients not able to consent
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10 participants (estimated)
Patient registry
No

Interventions

  • ProcedureCatheter ablation

    Mapping of the epicardium and ablating areas of long fractionated potentials

06

What researchers measure

Primary outcomes

  1. Eradication of Brugada syndrome pattern

    Disappearance of type 1 Brugada pattern on post-procedure ECG

    Time frame: 24h post procedure

Secondary outcomes

  1. Freedom from ventricular arrhythmias

    No documentation of sustained ventricular tachycardia or ventricular fibrillation

    Time frame: 12 months post-procedure

07

Study locations

3 of 3 sites recruiting
  • Instituto do Coracao
    São Paulo, Brazil
    Recruiting
  • Hospital de Santa Cruz
    Lisbon, Portugal
    Recruiting
  • St Bartholomew's Hospital
    London, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Patient data will be anonymised

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2017 (actual). Primary completion is estimated for Sep 2019, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 19, 2018
StartActual
Sep 1, 2017
Primary completionEst.
Sep 2019
CompletionEst.
Sep 2020
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03435393
Lead sponsor
University College London Hospitals
Responsible party
Rui Providência (Honorary Consultant, MD PhD, University College London Hospitals) — Principal investigator
First posted
Feb 19, 2018
Start date
Sep 1, 2017
Primary completion
Sep 2019 (estimated)
Completion
Sep 2020 (estimated)
Last update
Feb 19, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Brugada Syndrome →

Other studies from this sponsor

University College London Hospitals

Start the discussion